论文部分内容阅读
目的 评价血清胰岛素样生长因子结合蛋白 3(IGFBP 3)蛋白酶活性检测的临床意义。方法 应用Western印迹方法检测正常人、临产时孕妇、肢端肥大症及生长激素缺乏症 (GHD)病人血清中IGFBP 3蛋白酶的活性。结果 临产时孕妇、活动性肢端肥大症病人、正常人及治疗前GHD病人的血清IGFBP 3蛋白酶活性分别为 (75 .2± 2 .2 ) %、(6 8.6± 3.9) %、(2 2 .7± 3.1) %及 (13.4± 4.2 ) %。用重组人GH(rhGH)治疗 6个月后 ,GHD患者的血清IGFBP 3蛋白酶活性上升至 (2 9.0± 6 .8) %。结论 血清IGFBP 3蛋白酶活性既受GH的调节 ,又对GH IGF Ⅰ轴中各成员的血清水平具有调节作用
Objective To evaluate the clinical significance of serum insulin - like growth factor binding protein 3 (IGFBP 3) protease activity. Methods Western blotting was used to detect the activity of IGFBP 3 protease in the serum of pregnant women, acromegaly and GHD patients at the time of labor. Results Serum IGFBP3 protease activities of pregnant women, active acromegaly patients, normal subjects and pre-treatment GHD patients during labor were (75.2 ± 2.2)%, (6 8.6 ± 3.9)%, (2 2 .7 ± 3.1)% and (13.4 ± 4.2)%, respectively. After 6 months of treatment with recombinant human GH (rhGH), serum IGFBP3 protease activity increased to (2 9.0 ± 6 .8)% in GHD patients. Conclusions Serum IGFBP 3 protease activity is regulated both by GH and serum levels in each member of the GH IGF axis